Rechallenge of immunotherapy beyond progression in patients with extensive-stage small-cell lung cancer

Background: Rechallenge of immunotherapy beyond progression (RIBP) has been demonstrably effective in a variety of cancers. Our study aims to investigate the efficacy of RIBP in small-cell lung cancer (SCLC) patients under real-world conditions. Methods: SCLC patients who experienced progressive dis...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Lingling, Liu, Tingting, Liu, Qingyan, Mu, Shuai, Tao, Haitao, Yang, Xuhui, Li, Yao, Xiong, Qi, Wang, Lijie, Hu, Yi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9485935/
https://www.ncbi.nlm.nih.gov/pubmed/36147357
http://dx.doi.org/10.3389/fphar.2022.967559

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9485935/
https://www.ncbi.nlm.nih.gov/pubmed/36147357
http://dx.doi.org/10.3389/fphar.2022.967559

Ejemplares similares